Propanc Biopharma (PPCB) 10-Q 14 Nov 22 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Sep. 30, 2022	Nov. 11, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--06-30
Entity File Number	000-54878
Entity Registrant Name	PROPANC BIOPHARMA, INC.
Entity Central Index Key	0001517681
Entity Tax Identification Number	33-0662986
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell, VIC
Entity Address, Country	AU
Entity Address, Postal Zip Code	3124
City Area Code	+61-03
Local Phone Number	9882-0780
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		889,745,790

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Jun. 30, 2022
CURRENT ASSETS:
Cash	$ 19,396	$ 4,067
GST tax receivable	2,701	2,342
Prepaid expenses and other current assets	15,765	8,621
TOTAL CURRENT ASSETS	37,862	15,030
Security deposit - related party	1,930	2,075
Operating lease right-of-use assets, net - related party	53,025	62,523
Property and equipment, net	1,437	2,023
TOTAL ASSETS	94,254	81,651
CURRENT LIABILITIES:
Accounts payable	899,225	943,023
Accrued expenses and other payables	448,719	466,115
Convertible notes and related accrued interest, net of discounts and premiums	913,641	984,260
Operating lease liability - related party, current portion	14,516	20,605
Embedded conversion option liabilities	72,958	151,262
Due to former director - related party	28,599	30,746
Loan from former director - related party	47,597	51,171
Employee benefit liability	397,171	415,799
TOTAL CURRENT LIABILITIES	2,822,426	3,062,981
NON-CURRENT LIABILITIES:
Operating lease liability - long-term portion - related party	39,363	42,319
TOTAL NON-CURRENT LIABILITIES	39,363	42,319
TOTAL LIABILITIES	2,861,789	3,105,300
Commitments and Contingencies (See Note 8)
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; 10,000,000,000 shares authorized; 677,177,717 and 220,350,921 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively	677,178	220,351
Common stock issuable (1,309 and 19,597,024 shares as of September 30, 2022 and June 30, 2022, respectively)	1	19,597
Additional paid-in capital	57,800,241	57,124,982
Subscription receivable		(23,758)
Accumulated other comprehensive income	1,360,945	1,234,549
Accumulated deficit	(62,564,423)	(61,557,893)
Treasury stock (1 share)	(46,477)	(46,477)
TOTAL STOCKHOLDERS’ DEFICIT	(2,767,535)	(3,023,649)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	94,254	81,651
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock value	5,000	5,000
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Jun. 30, 2022
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	10,000,000,000	10,000,000,000
Common stock, shares issued	677,177,717	220,350,921
Common stock, shares outstanding	677,177,717	220,350,921
Common stock, shares issuable	1,309	19,597,024
Treasury stock, shares	1	1
Series A Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	500,000	500,000
Preferred stock, shares outstanding	500,000	500,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	465,132	431,740
Occupancy expenses - related party	6,373	7,736
Research and development	101,325	46,554
TOTAL OPERATING EXPENSES	572,830	486,030
LOSS FROM OPERATIONS	(572,830)	(486,030)
OTHER INCOME (EXPENSE)
Interest expense	(162,752)	(109,853)
Interest income	2
Change in fair value of derivative liabilities	65,173	(3,904)
Gain from settlement of accounts payable	17,499
Loss on extinguishment of debt, net	(610)
Foreign currency transaction gain	36,223	109,129
TOTAL OTHER EXPENSE, NET	(44,465)	(4,628)
LOSS BEFORE TAXES	(617,295)	(490,658)
Tax benefit
NET LOSS	(617,295)	(490,658)
Deemed Dividend	(389,235)	(114,844)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (1,006,530)	$ (605,502)
BASIC AND DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ 0	$ (0.02)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	473,589,083	27,142,519
OTHER COMPREHENSIVE INCOME
Unrealized foreign currency translation gain	$ 126,396	$ 64,193
TOTAL OTHER COMPREHENSIVE INCOME	126,396	64,193
TOTAL COMPREHENSIVE LOSS	$ (880,134)	$ (541,309)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Beginning balance, value at Jun. 30, 2021	$ 5,000		$ 14,056		$ 54,074,110		$ (58,199,466)	$ 1,085,204	$ (46,477)	$ (3,067,573)
Beginning balance, shares at Jun. 30, 2021	500,000	1	14,055,393	59
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 9,445		190,741					200,186
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			9,445,009
Issuance of common stock for services and accrued expenses			$ 17,934		563,927					581,861
Issuance of common stock for services and accrued expenses, shares			17,934,379
Issuance of common stock for exercise of warrants			$ 7	$ 2	374,991	(100,000)				275,000
Issuance of common stock for exercise of warrants, shares			6,875	2,500
Issuance of common stock for alternate cashless exercise of warrants			$ 2,400	$ 2,000	(4,400)
Issuance of common stock for alternate cashless exercise of warrants, shares			2,399,988	1,999,990
Reclassification of put premium upon debt conversion					109,643					109,643
Stock based compensation in connection with stock option grants					20,718					20,718
Foreign currency translation gain								64,193		64,193
Deemed dividend upon alternate cashless exercise of warrants					114,844		(114,844)
Net loss							(490,658)			(490,658)
Reclassification of put premium upon debt conversion										109,643
Ending balance, value at Sep. 30, 2021	$ 5,000		$ 43,842	$ 2,002	55,444,574	(100,000)	(58,804,968)	1,149,397	(46,477)	(2,306,630)
Ending balance, shares at Sep. 30, 2021	500,000	1	43,841,644	2,002,549
Beginning balance, value at Jun. 30, 2022	$ 5,000		$ 220,351	$ 19,597	57,124,982	(23,758)	(61,557,893)	1,234,549	(46,477)	(3,023,649)
Beginning balance, shares at Jun. 30, 2022	500,000	1	220,350,921	19,597,024
Issuance of common stock for exercise of warrants			$ 1	$ 1	99,998					100,000
Issuance of common stock for exercise of warrants, shares			1,250	1,250
Issuance of common stock for alternate cashless exercise of warrants			$ 158,399		(158,399)
Issuance of common stock for alternate cashless exercise of warrants, shares			158,399,208
Foreign currency translation gain								126,396		126,396
Deemed dividend upon alternate cashless exercise of warrants					389,235		(389,235)
Net loss							(617,295)			(617,295)
Issuance of common stock for cash			$ 14,337		10,374	23,758				48,469
Issuance of common stock for cash, shares			14,336,712
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 264,493		192,446					456,939
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			264,492,661
Issuance of common stock for issuable shares			$ 19,597	$ (19,597)
Issuance of common stock for issuable shares, shares			19,596,965	(19,596,965)
Reclassification of put premium upon debt conversion					133,646					133,646
Stock based compensation in connection with stock warrant grant					2,408					2,408
Stock warrant grant for settlement of accounts payable					5,551					5,551
Ending balance, value at Sep. 30, 2022	$ 5,000		$ 677,178	$ 1	$ 57,800,241		$ (62,564,423)	$ 1,360,945	$ (46,477)	$ (2,767,535)
Ending balance, shares at Sep. 30, 2022	500,000	1	677,177,717	1,309

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (617,295)	$ (490,658)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance and amortization of common stock for services		133,422
Foreign currency transaction gain	(36,223)	(109,129)
Depreciation expense	473	509
Amortization of debt discounts	31,275	6,074
Amortization of right-of-use assets	5,131
Change in fair value of derivative liabilities	(65,173)	3,904
Loss on extinguishment of debt, net	610
Gain from settlement of accounts payable	(17,499)
Stock option, stock warrants and restricted stock expense	2,408	20,718
Non-cash interest expense		2,250
Accretion of put premium	115,769	90,192
Changes in Assets and Liabilities:
GST receivable	(523)	1,937
Prepaid expenses and other assets	(7,747)	(8,353)
Accounts payable	45,121	(137,927)
Employee benefit liability	10,415	4,067
Accrued expenses and other payables	15,162	(15,102)
Accrued interest	13,430	11,338
Operating lease liability	(4,649)
NET CASH USED IN OPERATING ACTIVITIES	(509,315)	(486,758)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	345,750	160,000
Proceeds from the sale of common stock	24,711
Collection of subscription receivable	23,758
Proceeds from the exercise of warrants	100,000	275,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	494,219	435,000
Effect of exchange rate changes on cash	30,425	95,320
NET INCREASE IN CASH	15,329	43,562
CASH AT BEGINNING OF PERIOD	4,067	2,255
CASH AT END OF PERIOD	19,396	45,817
Supplemental Disclosure of Cash Flow Information
Interest	2,277
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Subscription receivable		100,000
Reduction of put premium related to conversions of convertible notes	133,646	109,643
Conversion of convertible notes and accrued interest to common stock	349,530	197,936
Discounts related to derivative liability	93,668
Stock warrant grant for settlement of accounts payable	23,050
Common stock issued for accrued services		448,440
Warrants issued for accrued services	5,551
Deemed dividend upon alternate cashless exercise of warrants	$ 389,235	$ 114,844

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	3 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2022, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. In July 2020, a world first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 45 granted, allowed, or accepted patents and 20 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation (the “Certificate”) with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005 On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 3,000,000,000 10,000,000,000 1,500,005 10,001,500,005 Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2022 and 2021 and cash flows for the three months ended September 30, 2022 and 2021 and our consolidated financial position at September 30, 2022 have been made. The Company’s results of operations for the three months ended September 30, 2022 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2023. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2022. The June 30, 2022 balance sheet is derived from those statements. PROPANC BIOPHARMA, INC. AND SUBSIDIARY Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through September 30, 2022. Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of September 30, 2022 and 2021, the Company recognized a cumulative exchange gain of approximately $ 1,226,000 619,000 As of September 30, 2022 and June 30, 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES September 30, 2022 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6432 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6836 0.7253 The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2022 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2022 $ 1,234,549 Unrealized foreign currency translation gain 126,396 Ending balance, September 30, 2022 $ 1,360,945 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). PROPANC BIOPHARMA, INC. AND SUBSIDIARY The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7 Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2022 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Employee Benefit Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of September 30, 2022, and June 30, 2022, the Company was owed $ 2,701 2,342 PROPANC BIOPHARMA, INC. AND SUBSIDIARY Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 101,325 46,554 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. During each of the three months ended September 30, 2022 and 2021, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 0 Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. PROPANC BIOPHARMA, INC. AND SUBSIDIARY Legal Expenses All legal costs for litigation are charged to expense as incurred. Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the notes has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2022 September 30, 2021 (Unaudited) (Unaudited) Stock Options 59 59 Stock Warrants with no designations 3,305,975 111,932 Series A Warrants as if converted at alternate cashless exercise price 2,030,789,846 - Series B Warrants 26,250 - Series C Warrants as if converted at alternate cashless exercise price * 7,499,962,500 - Unvested restricted stock 59 59 Convertible Debt 884,700,197 23,293,971 Total 10,418,784,886 23,406,021 * Only convertible ratably upon exercise of Series B Warrants Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on our consolidated financial statements.

GOING CONCERN

GOING CONCERN	3 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the three months ended September 30, 2022, the Company had no revenues, had a net loss of $ 617,295 509,315 2,784,564 2,767,535 62,564,423 The unaudited condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful. PROPANC BIOPHARMA, INC. AND SUBSIDIARY In March 2020, the outbreak of COVID-19 (coronavirus) caused by a novel strain of the coronavirus was recognized as a pandemic by the World Health Organization, and the outbreak has become increasingly widespread in the United States, Europe and Australia, including in each of the areas in which the Company operates. The COVID-19 (coronavirus) outbreak has had a notable impact on general economic conditions, including but not limited to the temporary closures of many businesses, “shelter in place” and other governmental regulations, reduced business and consumer spending due to both job losses, reduced investing activity and M&A transactions, among many other effects attributable to the COVID-19 (coronavirus), and there continue to be many unknowns. While to date the Company has not been required to stop operating, management is evaluating its use of its office space, virtual meetings and the like. The Company continues to monitor the impact of the COVID-19 (coronavirus) outbreak closely. The extent to which the COVID-19 (coronavirus) outbreak will impact our operations, ability to obtain financing or future financial results is uncertain.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following As of September 30, 2022 and June 30, 2022. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT September 30, 2022 June 30, 2022 (Unaudited) Office equipment at cost $ 28,600 $ 28,623 Less: Accumulated depreciation (27,163 ) (26,600 ) Total property, plant, and equipment $ 1,437 $ 2,023 Depreciation expense for the three months ended September 30, 2022 and 2021 were $ 473 509

DUE TO FORMER DIRECTOR - RELATE

DUE TO FORMER DIRECTOR - RELATED PARTY	3 Months Ended
	Sep. 30, 2022
Due To Former Director - Related Party
DUE TO FORMER DIRECTOR - RELATED PARTY	NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to former director - related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed the former director at September 30, 2022 and June 30, 2022 were $ 28,599 30,746

LOAN FROM FORMER DIRECTOR _ REL

LOAN FROM FORMER DIRECTOR – RELATED PARTY	3 Months Ended
	Sep. 30, 2022
Loan From Former Director Related Party
LOAN FROM FORMER DIRECTOR – RELATED PARTY	NOTE 5 – LOAN FROM FORMER DIRECTOR – RELATED PARTY Loan from Former Director - Related Party Loan from the Company’s former director at September 30, 2022 and June 30, 2022 was $ 47,597 51,171

CONVERTIBLE NOTES

CONVERTIBLE NOTES	3 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
CONVERTIBLE NOTES	NOTE 6 – CONVERTIBLE NOTES The Company’s convertible notes outstanding at September 30, 2022 and June 30, 2022 were as follows: SCHEDULE OF CONVERTIBLE DEBT September 30, 2022 June 30, 2022 (Unaudited) Convertible notes and debenture $ 697,280 $ 644,980 Unamortized discounts (127,811 ) (31,669 ) Accrued interest 48,922 57,822 Premium, net 295,250 313,127 Convertible notes, net $ 913,641 $ 984,260 PROPANC BIOPHARMA, INC. AND SUBSIDIARY Convertible Note Issued with Consulting Agreement August 10, 2017 Consulting Agreement On August 10, 2017, the Company entered into a consulting agreement, retroactive to May 16, 2017, with a certain consultant, pursuant to which the consultant agreed to provide certain consulting and business advisory services in exchange for a $ 310,000 August 10, 2017 10 750 65 ten August 10, 2019 155,000 155,000 18 578,212 140,000 10,764 161,000 19,418 9,000 500 5,248 8,500 22,168 On March 15, 2021, the Company entered into a Settlement and Mutual Release Agreement (the “Settlement Agreement”) with the consultant whereby both parties agreed to settle all claims and liabilities under the August 10, 2017 Convertible note for a total of $ 100,000 56,762 8,500 23,262 25,000 43,238 The total principal and accrued interest outstanding under the August 10, 2017 Convertible Note was $ 79,000 10,185 1,000 8,000 The total principal and accrued interest outstanding under the August 10, 2017 Convertible Note was $ 0 79,000 9,543 Crown Bridge Securities Purchase Agreements Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, pursuant to which Crown Bridge purchased a convertible promissory note (the “October 3, 2019 Crown Bridge Note”) from the Company in the aggregate principal amount of $ 108,000 3,000 5,000 100,000 October 3, 2019 15 Additionally, Crown Bridge has the option to convert all or any amount of the principal face amount of the October 3, 2019 Crown Bridge Note at any time from the date of issuance and ending on the later of the maturity date or the date the Default Amount is paid if an event of default occurs, which is an amount between 110 150 The conversion price for the October 3, 2019 Crown Bridge Note shall be equal to 60% ( representing a 40% discount) of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received 4.99 9.99 72,000 The October 3, 2019 Crown Bridge Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 15 The total principal amount outstanding under the above Crown Bridge financing agreement was $ 65,280 7,232 42,720 28,480 There were 15,000 st 9,600 6,400 16,000 The total principal amount outstanding under the above Crown Bridge financing agreement was $ 65,280 25,930 65,280 28,398 PROPANC BIOPHARMA, INC. AND SUBSIDIARY 1800 Diagonal Lending (formerly known as Sixth Street Lending) Securities Purchase Agreements October 21, 2021 Securities Purchase Agreement Effective October 21, 2021, the Company entered into a securities purchase agreement with Sixth Street Lending LLC (“Sixth Street”), pursuant to which Sixth Street purchased a convertible promissory note (the “October 21, 2021 Sixth Street”) from the Company in the aggregate principal amount of $ 63,750 3,750 October 21, 2022 8 November 26, 2021 Securities Purchase Agreement Effective November 26, 2021, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “November 26, 2021 Sixth Street”) from the Company in the aggregate principal amount of $ 53,750 3,750 November 26, 2022 8 January 4, 2022 Securities Purchase Agreement Additionally, effective January 4, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “January 4, 2022 Sixth Street”) from the Company in the aggregate principal amount of $ 63,750 3,750 January 4, 2023 8 March 7, 2022 Securities Purchase Agreement Additionally, effective March 7, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “March 7, 2022 Sixth Street”) from the Company in the aggregate principal amount of $ 68,750 3,750 March 7, 2023 8 April 12, 2022 Securities Purchase Agreement Effective April 12, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC, pursuant to which Sixth Street purchased a convertible promissory note (the “April 12, 2022 Sixth Street”) from the Company in the aggregate principal amount of $ 68,750 3,750 April 12, 2023 8 May 12, 2022 Securities Purchase Agreement Effective May 12, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), pursuant to which 1800 Diagonal purchased a convertible promissory note (the “May 12, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 63,750 3,750 May 12, 2023 8 PROPANC BIOPHARMA, INC. AND SUBSIDIARY June 30, 2022 Securities Purchase Agreement On June 30, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC, which closed on July 11, 2022, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 11, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 105,000 3,750 July 11, 2022 8 The following terms shall apply to all the above 1800 Diagonal notes: During the first 60 to 180 days following the date of the above listed notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 The conversion price for the above 1800 Diagonal notes shall be equal to 65 9.99 262,500 56,538 The above 1800 Diagonal notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22 Other than as described above, the above 1800 Diagonal notes contain certain events of default, including failure to timely issue shares upon receipt of a notice of conversion, as well as certain customary events of default, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, liquidation and failure by the Company to pay the principal and interest due under the Note. Additional events of default shall include, among others: (i) failure to reserve at least five times the number of shares issuable upon full conversion of the Note; (ii) bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Company or any subsidiary of the Company; provided, that in the event such event is triggered without the Company’s consent, the Company shall have sixty (60) days after such event is triggered to discharge such event, (iii) the Company’s failure to maintain the listing of the common stock on at least one of the OTC markets (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq Small Cap Market, the New York Stock Exchange, or the American Stock Exchange, (iv) The restatement of any financial statements filed by the Company with the SEC at any time after 180 days after the issuance date for any date or period until this note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have reasonably constituted a material adverse effect on the rights of 1800 Diagonal with respect to this note or the Purchase Agreement, and (v) the Company’s failure to comply with its reporting requirements of the Securities and Exchange Act of 1934 (the “Exchange Act”), and/or the Company ceases to be subject to the reporting requirements of the Exchange Act. In the event that the Company fails to deliver the shares of common stock issuable upon conversion of principal or interest under the above 1800 Diagonal notes within three business days of a notice of conversion by 1800 Diagonal, the Company shall incur a penalty of $ 1,000 Upon the occurrence and during the continuation of certain events of default, the above 1800 Diagonal notes will become immediately due and payable and the Company will pay 1800 Diagonal in full satisfaction of its obligations in the amount equal to 150 The total principal amount outstanding under the above 1800 Diagonal financing agreements were $ 265,000 6,081 117,500 4,700 63,269 The total principal amount outstanding under the above 1800 Diagonal financing agreements were $ 237,500 5,838 132,500 5,300 71,346 PROPANC BIOPHARMA, INC. AND SUBSIDIARY ONE44 Capital Securities Purchase Agreements December 7, 2021 Securities Purchase Agreement Effective December 7, 2021, the Company entered into a securities purchase agreement with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “December 7, 2021 ONE44”) from the Company in the aggregate principal amount of $ 170,000 25,500 December 7, 2022 10 March 29, 2022 Securities Purchase Agreement Effective March 29, 2022, the Company entered into a securities purchase agreement with ONE44 Capital LLC, pursuant to which ONE44 purchased a convertible promissory note (the “March 29, 2022 ONE44”) from the Company in the aggregate principal amount of $ 120,000 18,000 March 29, 2023 10 August 15, 2022 Securities Purchase Agreement On August 15, 2022, the Company entered into a securities purchase agreement with ONE44 Capital LLC, pursuant to which ONE44 Capital purchased a convertible redeemable note (the “August 15, 2022 ONE44 Note”) from the Company in the aggregate principal amount of $ 110,000 10,000 5,500 August 15, 2023 The following terms shall apply to all the above ONE44 notes: During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 120 135 The conversion price for the above ONE44 notes shall be equal to 65 4.99 215,385 59,231 The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 250 th 500 th 20 The total principal amount outstanding under the above ONE44 financing agreements were $ 235,700 9,519 54,300 2,873 29,238 The total principal amount outstanding under the above ONE44 financing agreements were $ 230,000 7,438 115,700 7,487 62,300 PROPANC BIOPHARMA, INC. AND SUBSIDIARY GS Capital Partners Securities Purchase Agreements August 12, 2022 Securities Purchase Agreement On August 12, 2022, the Company entered into a securities purchase agreement (the “GS Capital Purchase Agreement”) with GS Capital Partners, LLC (“GS Capital”), pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 93,000 5,000 3,000 The maturity date of the GS Capital Note is April 12, 2023 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock (“Conversion Price”) of $0.0028 per share (the “Fixed Price”). However, in the event the Company’s common stock trades below $0.002 per share for more than five (5) consecutive trading days, then the Fixed Price shall be equal to $0.0013 per share. 65 4.99 September 21, 2022 Securities Purchase Agreement On September 21, 2022, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 71,500 4,000 2,500 The maturity date of the GS Capital Note is March 21, 2023 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of the Company’s common stock (the “Common Stock”) at a price for each share of Common Stock (“Conversion Price”) of $0.002 per share (the “Fixed Price”). However, in the event the Company’s Common Stock trades below $0.0014 per share for more than five (5) consecutive trading days, then the Fixed Price shall be equal to $0.0009 per share. 65 4.99 During the first 60 to 180 days following the date of the above GS Capital notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to GS Capital, together with any other amounts that the Company may owe the holder under the terms of the notes, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest shall accrue at a default interest rate of 24 250 th 500 th 20 The total principal outstanding and accrued interest under the above GS Capital notes were $ 164,500 1,140 164,500 Convertible notes in default There is one convertible note that is currently past due and in default, consisting of $ 65,280 28,398 15 PROPANC BIOPHARMA, INC. AND SUBSIDIARY Amortization of debt discounts The Company recorded $ 127,418 7,500 115,769 90,192 Amortization of all debt discounts for the three months ended September 30, 2022 and 2021 was $ 31,275 6,074 The Company reclassified $ 133,646 109,643

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	3 Months Ended
	Sep. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 7 – STOCKHOLDERS’ DEFICIT Increase in Authorized Shares of Common Stock and Reverse Stock Split On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005 On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 3,000,000,000 10,000,000,000 1,500,005 10,001,500,005 Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005 0.01 Of the total preferred shares authorized, 500,000 500,000 Of the total preferred shares authorized, pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on June 16, 2015, up to five shares have been designated as Series B Preferred Stock (“Series B Preferred Stock”). Each holder of outstanding shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of the Company. One one No Common Stock: Shares issued for Common Stock Purchase Agreement On November 30, 2021, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Dutchess Capital Growth Fund LP, a Delaware limited partnership, (“Dutchess”), providing for an equity financing facility (the “Equity Line”). The Purchase Agreement provides that upon the terms and subject to the conditions in the Purchase Agreement, Dutchess is committed to purchase up to Five Million Dollars ($ 5,000,000 36 PROPANC BIOPHARMA, INC. AND SUBSIDIARY Under the terms of the Purchase Agreement, Dutchess will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Dutchess’ resale of any Common Stock purchased by Dutchess under the Equity Line. From time to time over the 36-month term of the Purchase Agreement, commencing on the trading day immediately following the date on which the Registration Statement becomes effective, the Company, in our sole discretion, may provide Dutchess with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 92 The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 300 250,000 On July 13, 2022, the Company issued 14,336,712 0.002 24,711 23,758 Shares issued for conversion of convertible debt As of June 30, 2022, there was common stock issuable of 7,326,007 7,326,007 From July 1, 2022 through September 14, 2022, the Company issued an aggregate of 264,492,661 0.001 327,200 22,330 456,939 The Company reclassified $ 133,646 During the three months ended September 30, 2022, converted notes - principal of $ 79,000 9,543 195,952 107,409 106,799 610 The Company has 1,565,029,216 Shares issued for services and accrued expenses As of June 30, 2022, there was common stock issuable of 12,270,958 12,270,958 Shares issued for exercise of warrants Between July 29, 2022 and September 9, 2022, the Company received gross proceeds of $ 100,000 2,500 1,250 1,250 1,250 During the three months ended September 30, 2022, the Company issued 158,399,208 792 200 0.001 200 70 389,235 PROPANC BIOPHARMA, INC. AND SUBSIDIARY Restricted Stock Units Pursuant to employment agreements dated in May 2019, the Company granted an aggregate of 78 39 117 4,250 497,240 248,620 59 248,620 Warrants: The following table summarizes warrant activity for the three months ended September 30, 2022: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2022 105,420 $ 200.27 Granted 3,305,000 0.01 Exercised (3,292 ) 78.49 Forfeited (1,000 ) 2,000.00 Expired - - Outstanding at September 30, 2022 3,406,128 * $ 5.55 Exercisable at September 30, 2022 3,379,879 $ 2.83 Outstanding and Exercisable: Weighted average remaining contractual term 2.83 Aggregate intrinsic value $ - * The total warrants of 3,406,128 SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10,154 10,154 Series B warrants 26,250 26,250 Series C warrants 63,749 37,500 Warrants with no class designation 3,305,975 3,305,975 Total 3,406,128 3,379,879 On August 16, 2022, the Company entered into an agreement with a certain consultant to provide services over a three-month period in exchange for 1,000,000 0.01 August 16, 2025 2,408 0.0026 0.01 zero 3.00 3.19 236 2,408 On August 16, 2022, the Company and a third-party investor relations consultant agreed to settle an outstanding payable of $ 23,050 2,305,000 0.01 5,551 0.0026 0.01 zero 3.00 3.19 236 17,499 Options: A summary of the Company’s option activity during the three months ended September 30, 2022 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Exercise Shares Price Per Share Outstanding at June 30, 2022 59 $ 4,533 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2022 59 $ 4,533 Exercisable at September 30, 2022 59 $ 4,533 Outstanding and Exercisable: Weighted average remaining contractual term 6.62 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ - PROPANC BIOPHARMA, INC. AND SUBSIDIARY On the Effective Date, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 234 During the three months ended September 30, 2022 and 2021, the Company recognized stock-based compensation of $ 0 20,718 0 No

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be subject to litigation and claims arising in the ordinary course of business. The Company is not currently a party to any material legal proceedings and the Company is not aware of any pending or threatened legal proceeding against the Company that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company’s parent U.S. entity is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $ 10,000 30,000 Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “University”) whereby the Company and the University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property while agreeing to pay royalties of 2 5 Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 59,508 40,000 45,775 31,754 36,117 28,493 24,043 30,000 35,145 5,000 5,000 5,858 10,000 11,715 10,000 11,715 25,837 30,268 2 On July 27, 2022, the Company entered into a two-year research agreement with the University of Jaén to provide certain research and experiment services to the Company. In exchange for full ownership of the intellectual property the Company agreed to pay royalties of 2 53,200 53,806 - 18,200 18,407 - 8,000 8,091 - 7,000 7,080 - 10,000 10,114 - 10,000 10,114 The commencement date for the experiments was on September 1, 2022, and the estimated length of time for completion is 24 months. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 (Unaudited) As of September 30, 2022 and June 30, 2022, the Company has $ 13,360 14,364 Consulting Agreement On July 1, 2022, the Company and a consultant agreed to extend the term of a consulting agreement from July 1, 2022 to June 30, 2023 to provide media related services for a monthly fee of $ 50,000 9.9 9.9 54,765 Operating Leases On May 4, 2022, the Company entered in a three 3,000 2,176 66,201 66,201 ROU is summarized below: SCHEDULE OF RIGHT USE OF ASSET September 30, 2022 June 30, 2022 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (13,176 ) (3,678 ) Right-of-use asset, net $ 53,025 $ 62,523 Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY September 30, 2022 June 30, 2022 Office lease $ 66,201 $ 66,201 Reduction of lease liability (12,322 ) (3,277 ) Less: office lease, current portion (14,516 ) (20,605 ) Long term portion of lease liability $ 39,363 $ 42,319 Remaining future minimum lease payments under non-cancelable operating lease at September 30, 2022 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2023 $ 17,366 Fiscal Year 2024 23,155 Fiscal Year 2025 19,296 Imputed interest (5,938 ) Total operating lease liability $ 53,879 The weighted average remaining lease term for the operating lease is 2.52

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of September 30, 2022 and June 30, 2022, the Company owed its former director a total of $ 28,599 30,746 As of September 30, 2022 and June 30, 2022, the Company owed its former director a total of $ 47,597 51,171 On May 4, 2022, the Company entered into a three 3,000 2,176 131,129 84,342 122,129 84,452 6,373 7,736 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 (Unaudited) Employment and Services Agreements with Management The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019 25,000 300,000 205,680 9.5 200 300,000 205,680 400,000 274,240 400,000 276,600 600,000 414,900 Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $ 120,000 80,904 Pursuant to a February 25, 2016 board resolution, James Nathanielsz shall be paid $ 4,481 3,205 7,689 5,577 Pursuant to the approval of the Company’s board of directors, on May 14, 2019, Mr. Nathanielsz was granted a $ 460,000 315,376 200,000 137,120 260,000 178,256 90,000 64,377 240,000 60 202,620 136,606 407,380 280,726 177,840 221,890 166,418 422,610 316,957 177,840 5,928,000 140,000 96,810 144,166 99,691 181,324 125,386 41,387 26,620 139,937 90,007 Amended and Restated Employment Agreement - On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with James Nathanielsz, the Company’s Chief Executive Officer, Chairman, acting Chief Financial Officer and a director, for a term of three years one 400,000 39 4,675 110 4,250 39 39 The Nathanielsz Options have a term of 10 7.80 7.80 4,000,000 7.80 7.80 39 600,000 414,900 100 200 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 (Unaudited) Amended and Restated Services Agreement - On May 14, 2019, the Company also entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three years one 54,000 20 4,250 100 20 20 The Kenyon Options have a term of 10 5 5 4,000,000 5 5 20 102,600 3,420,000 67,500 43,416 54,000 37,341 Collaboration Agreement On October 1, 2020, the Company entered into a two-year collaboration agreement with the University of Jaén to provide certain research services to the Company. One of the Company’s Scientific Advisory Board is the lead joint researcher of University of Jaén. Additionally, on July 27, 2022, the Company entered into a two-year research agreement with the University of Jaén to provide certain research and experiment services to the Company (see Note 8). Further, the Company agreed to pay royalties of 1% of net revenues each to two members of the Scientific Advisory Board. Intercompany Loans All Intercompany loans were made by the parent to the subsidiary, Propanc PTY LTD, which have not been repaid as of September 30, 2022. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment on the consolidated balance sheet as accumulated other comprehensive income.

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	3 Months Ended
	Sep. 30, 2022
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND RISKS	NOTE 10 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through September 30, 2022. The Company primarily relied on funding from three convertible debt lenders and received net proceeds after deductions of $ 33,750 101,250 94,500 150,000 29 27 44 The Company primarily relied on funding from one convertible debt lender and received proceeds after deductions of $ 7,500 160,000 100 Receivable Concentration As of September 30, 2022 and June 30, 2022, the Company’s receivables were 100 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 (Unaudited) Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea, India and Brazil. In Canada, the patent application remains under examination. In 2016 and early 2017, we filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application is currently entering national phase in August 2018. A third PCT application entered the national phase in October 2018. In July 2020, a world first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 45 granted, allowed, or accepted patents and 20 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of September 30, 2022 and June 30, 2022, the Company’s operations are based in Camberwell, Australia, however the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2022 and June 30, 2022, there has been no activity within this entity.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	3 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 11 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity 164,500 79,000 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at September 30, 2022, the last trading day of the period ended September 30, 2022, was $ 0.0012 Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations (on new derivative instruments entered into during the three months ended September 30, 2022) September 30, 2022 Volatility 228.29 250.04 % 250.04 % Expected Remaining Term (in years) 0.50 0.67 0.47 0.53 Risk Free Interest Rate 3.13 3.86 % 3.92 % Expected dividend yield None None PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 (Unaudited) Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and June 30, 2022: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at September 30, Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 72,958 $ — $ — $ 72,958 Total $ 72,958 $ — $ — $ 72,958 Balance at June 30, Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 151,262 $ — $ — $ 151,262 Total $ 151,262 $ — $ — $ 151,262 The following is a roll forward for the three months ended September 30, 2022 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2022 $ 151,262 Initial fair value of embedded conversion option derivative liability recorded as debt discount 93,668 Reduction of derivative liability upon debt conversion (106,799 ) Change in fair value included in statements of operations (65,173 ) Balance at September 30, 2022 $ 72,958

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS Shares issued for conversion of convertible debt Between October 2022 and November 2022, the Company issued an aggregate of 97,854,629 0.001 57,400 30,908 Red Road Holdings Securities Purchase Agreement On October 6, 2022, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Red Road Holdings Corporation, a Virginia corporation (“Red Road”), pursuant to which Red Road purchased a convertible promissory note (the “Note”) from the Company in the aggregate principal amount of $ 53,750 50,000 8 22 3,750 The conversion price for the Note shall be equal to the Variable Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Company relating to the Company’s securities or the securities of any subsidiary of the Company, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The “Variable Conversion Price” shall mean 65% multiplied by the Market Price (as defined herein) (representing a discount rate of 35%). “Market Price” means the average of the lowest three (3) Trading Prices (as defined below) for the common stock during the ten (10) trading days prior to the conversion date. Notwithstanding the foregoing, Red Road shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Red Road and its affiliates, exceeds 4.99 28,942 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 (Unaudited) The Note may be prepaid until 180 days from the issuance date. If the Note is prepaid within 60 days of the issuance date, then the prepayment premium shall be 110% of the face amount plus any accrued interest, if prepaid after 60 days from the issuance date, but less than 91 days from the issuance date, then the prepayment premium shall be 115% of the face amount plus any accrued interest, if prepaid after 90 days from the issuance date, but less than 121 days from the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest, if prepaid after 120 days from the issuance date, but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest, and if prepaid after 150 days from the issuance date, but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest. So long as the Note is outstanding, the Company covenants not to, without prior written consent from Red Road, sell, lease or otherwise dispose of all or substantially all of its assets outside the ordinary course of business which would render the Company a “shell company” as such term is defined in Rule 144. In the event that the Company fails to deliver to Red Road shares of common stock issuable upon conversion of principal or interest under the Note within three business days of a notice of conversion by Red Road, the Company shall incur a penalty of $ 1,000 Shares issued for exercise of warrants In October 2022, the Company issued 33,599,832 19,322 In October 2022, the Company received aggregate gross proceeds of $ 50,000 1,250 1,250 Shares issued for services In October 2022, the Company issued 6,111,112 0.0009 5,500 Amended and Restated Employment Agreement On October 26, 2022, the Company entered into an Amended and Restated Employment Agreement (the “Amended Agreement”) with James Nathanielsz, the Company’s Chief Executive Officer and Chief Financial Officer (the “Executive”), effective as of July 1, 2022, (the “Effective Date”). The Amended Agreement provides the Executive with a base salary of $ 600,000 414,900 100 200 In the event that the Company provides notice of non-renewal of Executive’s Amended Agreement, the Company terminates Executive without cause (as defined in the Amended Agreement) or Mr. Nathanielsz terminates his employment for good reason (as defined in the Amended Agreement), the Company has agreed to pay Executive a severance payment in an amount equal to Executive’s base salary for the year of termination in addition to accrued but unpaid salary, reimbursement of expenses, and certain other employee benefits as determined under the terms of the applicable plans (“Accrued Amounts”). In the event that Executive provides notice of non-renewal of the Amended Agreement, the Company terminates Mr. Nathanielsz for cause (as defined in the Amended Agreement) or Executive terminates his employment without good reason, Executive is only entitled to the Accrued Amounts. The Company has agreed to indemnify Executive for any liabilities, costs and expenses incurred in the event that Executive is made a party to a proceeding due to his roles with the Company, other than any proceeding initiated by Executive or the Company relating to any dispute with respect to the Amended Agreement or Executive’s employment. Under the terms of the Amended Agreement, the Executive is also subject to certain restrictive covenants, including a one-year non-compete. Increase in Authorized Shares On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 3,000,000,000 10,000,000,000 1,500,005 10,001,500,005 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2022 (Unaudited) Common Stock Purchase Agreement On November 3, 2022, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Coventry Enterprises, LLC, a Delaware limited company, (“Coventry”), providing for an equity financing facility (the “Equity Line”). The Purchase Agreement provides that upon the terms and subject to the conditions in the Purchase Agreement, Coventry is committed to purchase up to Five Million Dollars ($ 5,000,000 36 Under the terms of the Purchase Agreement, Coventry will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Coventry’s resale of any Common Stock purchased by Coventry under the Equity Line. From time to time over the 36-month term of the Purchase Agreement, commencing on the trading day immediately following the date on which the Registration Statement becomes effective, the Company, in our sole discretion, may provide Coventry with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 80% of the lowest volume weighted average price of the Common Stock during the 10 business days immediately preceding the Drawdown Notice date. The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 200 250,000 9.99 Coventry Enterprises, LLC Securities Purchase Agreement On November 3, 2022, the Company entered into a securities purchase agreement with Coventry Enterprises, LLC pursuant to which Coventry purchased a promissory note from the Company in the aggregate principal amount of $ 125,000 25,000 100,000 The Coventry note shall bear interest at a rate of 10 12,500 19,643 Additionally, in the event that while this note has been outstanding for four months, there is a REG A effective, then the Investor may choose to convert any amount up to the entire balance of the note including guaranteed interest into shares at the REG A offering price. At any time following an event of default under 7(a)(i), this note shall become convertible, in whole or in part, into shares of Common Stock at the option of the holder, at any time and from time to time thereafter (subject to the beneficial ownership limitations set forth in Section 5d). The conversion price of this note is ninety percent (90%) per share of the lowest per-share VWAP during the twenty (20) trading day period before the conversion (each, a “Calculated Conversion Price”). In the event that, within 30 calendar days either before or after any conversion, the conversion price of which is based upon a Calculated Conversion Price, the Company consummates (in whole or in part) any financing (whether such financing is equity, equity-equivalent, or debt or any combination thereof ) or for any other reason issues any shares of its Common Stock or any Common Stock Equivalents at a price less than the such most recent Calculated Conversion Price (the “Alternative Conversion Price”), regardless of when that note or instrument was originated, then, in respect of such conversion and at the option of the Holder, (i) if the conversion shall not then have yet occurred, then the Alternative Conversion Price shall be substituted for the Calculated Conversion Price and (ii) if the conversion shall already have occurred, then, within two Trading Days following the written request from the Holder therefor, the Company shall issue to the Holder that number of shares of Common Stock equivalent to the difference between the number of shares of Common Stock that had been issued using the Calculated Conversion Price and the number of shares of Common Stock that would have been issued using the Alternative Conversion Price. Upon the occurrence and during the continuation of certain events of default, interest shall accrue at a default interest rate which shall be equal to the lesser of i) 18% per annum or ii) the maximum rate permitted by law. Subject to the beneficial ownership limitation as set forth in Section 5(d), if any event of default occurs, then the outstanding principal amount of this note, the outstanding guaranteed interest amount of this note, plus accrued but unpaid default rate interest, liquidated damages and other amounts owing in respect thereof through the date of acceleration, shall become, at the Holder’s election, immediately due and payable at the holder’s option, in cash or in shares of Common Stock, at the mandatory default amount which payment is equal to 120% of the outstanding principal amount of this note and accrued and unpaid interest hereon, in addition to the payment of all other amounts, costs, expenses, and liquidated damages due in respect of this note. In the event that the Company fails to deliver to Coventry shares of Common Stock issuable upon conversion of principal or interest, the Company shall pay in cash which is equivalent to the amount in excess of the sales value of the shares of common stock that Coventry would be entitled to receive from the conversion over the principal amount and interest of the attempted conversion. As an additional inducement to the Coventry purchasing this note, the Company shall, as of the Original Issue Date and for no additional consideration, issue to the holder an aggregate of 75,000,000 0.0008 60,000

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	3 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of September 30, 2022, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. In July 2020, a world first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 45 granted, allowed, or accepted patents and 20 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation (the “Certificate”) with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005 On September 21, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 3,000,000,000 10,000,000,000 1,500,005 10,001,500,005
Basis of Presentation	Basis of Presentation The Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our consolidated results of operations for the three months ended September 30, 2022 and 2021 and cash flows for the three months ended September 30, 2022 and 2021 and our consolidated financial position at September 30, 2022 have been made. The Company’s results of operations for the three months ended September 30, 2022 are not necessarily indicative of the operating results to be expected for the full fiscal year ending June 30, 2023. Certain information and disclosures normally included in the notes to the Company’s annual audited consolidated financial statements have been condensed or omitted from the Company’s interim unaudited condensed consolidated financial statements included in this Quarterly Report. Accordingly, these interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2022. The June 30, 2022 balance sheet is derived from those statements. PROPANC BIOPHARMA, INC. AND SUBSIDIARY
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through September 30, 2022.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). As of September 30, 2022 and 2021, the Company recognized a cumulative exchange gain of approximately $ 1,226,000 619,000 As of September 30, 2022 and June 30, 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES September 30, 2022 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6432 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6836 0.7253 The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2022 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2022 $ 1,234,549 Unrealized foreign currency translation gain 126,396 Ending balance, September 30, 2022 $ 1,360,945
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). PROPANC BIOPHARMA, INC. AND SUBSIDIARY The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 11 - Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the balance sheets. There were no
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
Patents	Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through September 30, 2022 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Employee Benefit Liability	Employee Benefit Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months.
Australian Goods and Services Tax (“GST”)	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of September 30, 2022, and June 30, 2022, the Company was owed $ 2,701 2,342 PROPANC BIOPHARMA, INC. AND SUBSIDIARY
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes With Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 101,325 46,554 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. During each of the three months ended September 30, 2022 and 2021, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 0
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. PROPANC BIOPHARMA, INC. AND SUBSIDIARY
Legal Expenses	Legal Expenses All legal costs for litigation are charged to expense as incurred.
Leases	Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the notes has agreed to a 4.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2022 September 30, 2021 (Unaudited) (Unaudited) Stock Options 59 59 Stock Warrants with no designations 3,305,975 111,932 Series A Warrants as if converted at alternate cashless exercise price 2,030,789,846 - Series B Warrants 26,250 - Series C Warrants as if converted at alternate cashless exercise price * 7,499,962,500 - Unvested restricted stock 59 59 Convertible Debt 884,700,197 23,293,971 Total 10,418,784,886 23,406,021 * Only convertible ratably upon exercise of Series B Warrants
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40), which eliminates the beneficial conversion and cash conversion accounting models for convertible instruments, amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions, and modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS calculation. The standard is effective for annual periods beginning after December 15, 2023 for smaller reporting companies, and interim periods within those reporting periods. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those reporting periods. The Company is currently assessing the impact the new guidance will have on our consolidated financial statements.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	3 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF TRANSLATION EXCHANGE RATES	As of September 30, 2022 and June 30, 2022, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES September 30, 2022 June 30, 2022 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6432 0.6915 Average exchange rate for the period USD : AUD exchange rate 0.6836 0.7253
SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS	The change in Accumulated Other Comprehensive Income by component during the three months ended September 30, 2022 was as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Balance, June 30, 2022 $ 1,234,549 Unrealized foreign currency translation gain 126,396 Ending balance, September 30, 2022 $ 1,360,945
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE	The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE September 30, 2022 September 30, 2021 (Unaudited) (Unaudited) Stock Options 59 59 Stock Warrants with no designations 3,305,975 111,932 Series A Warrants as if converted at alternate cashless exercise price 2,030,789,846 - Series B Warrants 26,250 - Series C Warrants as if converted at alternate cashless exercise price * 7,499,962,500 - Unvested restricted stock 59 59 Convertible Debt 884,700,197 23,293,971 Total 10,418,784,886 23,406,021 * Only convertible ratably upon exercise of Series B Warrants

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consist of the following As of September 30, 2022 and June 30, 2022. SCHEDULE OF PROPERTY PLANT AND EQUIPMENT September 30, 2022 June 30, 2022 (Unaudited) Office equipment at cost $ 28,600 $ 28,623 Less: Accumulated depreciation (27,163 ) (26,600 ) Total property, plant, and equipment $ 1,437 $ 2,023

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	3 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE DEBT	The Company’s convertible notes outstanding at September 30, 2022 and June 30, 2022 were as follows: SCHEDULE OF CONVERTIBLE DEBT September 30, 2022 June 30, 2022 (Unaudited) Convertible notes and debenture $ 697,280 $ 644,980 Unamortized discounts (127,811 ) (31,669 ) Accrued interest 48,922 57,822 Premium, net 295,250 313,127 Convertible notes, net $ 913,641 $ 984,260

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	3 Months Ended
	Sep. 30, 2022
Equity [Abstract]
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes warrant activity for the three months ended September 30, 2022: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Shares Price Per Share Outstanding at June 30, 2022 105,420 $ 200.27 Granted 3,305,000 0.01 Exercised (3,292 ) 78.49 Forfeited (1,000 ) 2,000.00 Expired - - Outstanding at September 30, 2022 3,406,128 * $ 5.55 Exercisable at September 30, 2022 3,379,879 $ 2.83 Outstanding and Exercisable: Weighted average remaining contractual term 2.83 Aggregate intrinsic value $ - * The total warrants of 3,406,128
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE	SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10,154 10,154 Series B warrants 26,250 26,250 Series C warrants 63,749 37,500 Warrants with no class designation 3,305,975 3,305,975 Total 3,406,128 3,379,879
SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY	A summary of the Company’s option activity during the three months ended September 30, 2022 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Exercise Shares Price Per Share Outstanding at June 30, 2022 59 $ 4,533 Granted - - Exercised - - Forfeited - - Expired - - Outstanding at September 30, 2022 59 $ 4,533 Exercisable at September 30, 2022 59 $ 4,533 Outstanding and Exercisable: Weighted average remaining contractual term 6.62 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ -

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF RIGHT USE OF ASSET	ROU is summarized below: SCHEDULE OF RIGHT USE OF ASSET September 30, 2022 June 30, 2022 Office lease $ 66,201 $ 66,201 Less: accumulated amortization (13,176 ) (3,678 ) Right-of-use asset, net $ 53,025 $ 62,523
SCHEDULE OF OPERATING LEASE LIABILITY	Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY September 30, 2022 June 30, 2022 Office lease $ 66,201 $ 66,201 Reduction of lease liability (12,322 ) (3,277 ) Less: office lease, current portion (14,516 ) (20,605 ) Long term portion of lease liability $ 39,363 $ 42,319
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS	Remaining future minimum lease payments under non-cancelable operating lease at September 30, 2022 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2023 $ 17,366 Fiscal Year 2024 23,155 Fiscal Year 2025 19,296 Imputed interest (5,938 ) Total operating lease liability $ 53,879

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES	SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES Initial Valuations (on new derivative instruments entered into during the three months ended September 30, 2022) September 30, 2022 Volatility 228.29 250.04 % 250.04 % Expected Remaining Term (in years) 0.50 0.67 0.47 0.53 Risk Free Interest Rate 3.13 3.86 % 3.92 % Expected dividend yield None None
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at September 30, Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 72,958 $ — $ — $ 72,958 Total $ 72,958 $ — $ — $ 72,958 Balance at June 30, Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 151,262 $ — $ — $ 151,262 Total $ 151,262 $ — $ — $ 151,262
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE	The following is a roll forward for the three months ended September 30, 2022 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2022 $ 151,262 Initial fair value of embedded conversion option derivative liability recorded as debt discount 93,668 Reduction of derivative liability upon debt conversion (106,799 ) Change in fair value included in statements of operations (65,173 ) Balance at September 30, 2022 $ 72,958

SCHEDULE OF TRANSLATION EXCHANG

SCHEDULE OF TRANSLATION EXCHANGE RATES (Details)	Sep. 30, 2022	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6432	0.6915
Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6836	0.7253

SCHEDULE OF ACCUMULATED OTHER C

SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS (Details)	3 Months Ended
	Sep. 30, 2022 USD ($)
Accounting Policies [Abstract]
Beginning balance	$ 1,234,549
Foreign currency translation loss	126,396
Ending balance	$ 1,360,945

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE (Details)	3 Months Ended
	Sep. 30, 2022
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant And equipment	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant And equipment	7 years

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares		3 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		10,418,784,886	23,406,021
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		59	59
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		3,305,975	111,932
Series A Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		2,030,789,846
Series B Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		26,250
Series C Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	[1]	7,499,962,500
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		59	59
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total		884,700,197	23,293,971
[1]Only convertible ratably upon exercise of Series B Warrants

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Narrative) - USD ($)				3 Months Ended
	Sep. 21, 2022	Jul. 13, 2022	May 18, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 20, 2022	Jun. 30, 2022	May 17, 2022
Property, Plant and Equipment [Line Items]
Common stock, par value	$ 0.001		$ 0.001	$ 0.001			$ 0.001
Common stock, shares authorized	10,000,000,000		3,000,000,000	10,000,000,000		3,000,000,000	10,000,000,000	1,000,000,000
New issuance, shares	10,001,500,005		3,001,500,005
Cash and cash equivalents				$ 0			$ 0
Value added tax receivable				2,701			$ 2,342
Total research and development expense				101,325	$ 46,554
Tax credit				$ 0	0
Beneficial ownership conversion description				Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance
beneficial ownership percentage				4.99%
Intercompany Loans [Member]
Property, Plant and Equipment [Line Items]
Subsidiary exchange repayments				$ 1,226,000	$ 619,000
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Common stock, par value	$ 0.001		$ 0.001
New issuance, shares		14,336,712		14,336,712
Common Stock [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Common stock, shares authorized	3,000,000,000		1,000,000,000
Common Stock [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Common stock, shares authorized	10,000,000,000		3,000,000,000
Preferred Stock [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Common stock, shares authorized	1,500,005		1,500,005

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 617,295
Operating activities	509,315	$ 486,758
Working capital deficit	2,784,564
Stockholders equity	2,767,535	$ 2,306,630	$ 3,023,649	$ 3,067,573
Retained earnings accumulated deficit	$ 62,564,423		$ 61,557,893

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2022	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Office equipment at cost	$ 28,600	$ 28,623
Less: Accumulated depreciation	(27,163)	(26,600)
Total property, plant, and equipment	$ 1,437	$ 2,023

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 473	$ 509

DUE TO FORMER DIRECTOR - RELA_2

DUE TO FORMER DIRECTOR - RELATED PARTY (Details Narrative) - USD ($)	Sep. 30, 2022	Jun. 30, 2022
Due To Former Director - Related Party
Due to related parties current	$ 28,599	$ 30,746

LOAN FROM FORMER DIRECTOR _ R_2

LOAN FROM FORMER DIRECTOR – RELATED PARTY (Details Narrative) - USD ($)	Sep. 30, 2022	Jun. 30, 2022
Directors and Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Loans payable	$ 47,597	$ 51,171

SCHEDULE OF CONVERTIBLE DEBT (D

SCHEDULE OF CONVERTIBLE DEBT (Details) - USD ($)	Sep. 30, 2022	Jun. 30, 2022
Debt Disclosure [Abstract]
Convertible notes and debenture	$ 697,280	$ 644,980
Unamortized discounts	(127,811)	(31,669)
Accrued interest	48,922	57,822
Premium, net	295,250	313,127
Convertible notes, net	$ 913,641	$ 984,260

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative)																1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 21, 2022 USD ($)	Aug. 15, 2022 USD ($)	Aug. 12, 2022 USD ($)	May 12, 2022 USD ($)	Apr. 12, 2022 USD ($)	Mar. 29, 2022 USD ($)	Mar. 07, 2022 USD ($)	Jan. 04, 2022 USD ($)	Dec. 07, 2021 USD ($)	Nov. 26, 2021 USD ($)	Oct. 21, 2021 USD ($)	Sep. 16, 2020 shares	Oct. 03, 2019 USD ($)	Aug. 10, 2017 USD ($) Integer	Aug. 10, 2017 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Mar. 15, 2021 USD ($)	Nov. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)
Short-Term Debt [Line Items]
Convetible notes														$ 310,000	$ 310,000
Debt instrument maturity date														Aug. 10, 2017
Lowest trading price percentage																	4.99%
Embedded derivative fair value of embedded derivative liability																$ 151,262	$ 72,958		$ 151,262
Debt instrument face amount																	79,000
Accrued interest																57,822	48,922		57,822
Liabilities																3,105,300	2,861,789		3,105,300
Gains losses on extinguishment of debt																	(610)
Original issue discount																31,669	127,811		31,669
Convertible debt																	345,750	160,000
Debt instrument unamortized premium																313,127	295,250		313,127
Debt instrument amount																644,980	697,280		644,980
Original issue discounts amount																	33,750	7,500
Amortization of debt discount																	31,275	6,074
Reduction of put premium related to conversions of convertible notes																	133,646	109,643
One Convertible Notes [Member]
Short-Term Debt [Line Items]
Convetible notes																	$ 65,280
Interest rate																	15%
Accrued interest																	$ 28,398
1800 Diagonal Lending [Member] | May 12, 2022 1800 Diagonal Note [Member]
Short-Term Debt [Line Items]
Accrued interest																4,700			4,700
1800 Diagonal Lending [Member] | July 11 2022 1800 Diagonal Note [Member]
Short-Term Debt [Line Items]
Accrued interest																	5,300
ONE44 Capital LLC [Member]
Short-Term Debt [Line Items]
Accrued interest																	7,487
ONE44 Capital LLC [Member] | March 29, 2022 Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Accrued interest																2,873			2,873
August 10, 2017 Consulting Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date														Aug. 10, 2019
Interest rate														10%	10%
Debt conversion converted instrument														$ 750			79,000		1,000		$ 500
Lowest trading price percentage														65%
Debt instrument convertible | Integer														10
Accrued liabilities current and non current																					5,248				$ 155,000	$ 155,000
Debt instrument debt default interest rate															18%
Embedded derivative fair value of embedded derivative liability														$ 578,212	$ 578,212
Debt instrument face amount																					8,500			$ 9,000
Accrued interest																8,000	9,543		8,000		22,168
August 10, 2017 Consulting Agreement [Member] | Settlement and Mutual Release Agreement [Member]
Short-Term Debt [Line Items]
Convetible notes														$ 79,000	$ 79,000							$ 100,000
Accrued liabilities current and non current																						25,000
Debt instrument face amount																						8,500
Accrued interest																10,185	0		10,185			23,262
Liabilities																						$ 56,762
Gains losses on extinguishment of debt																				$ 43,238
August 10, 2017 Consulting Agreement [Member] | Consultant [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																								161,000	140,000
Accrued interest																								$ 19,418	$ 10,764
Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Original issue discount																	115,769	90,192
Amortization of debt discount																	127,418	$ 7,500
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																							$ 9,600
Debt instrument unamortized premium																							6,400
Unissued shares conversion | shares												15,000
Equity conversion																							$ 16,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date													Oct. 03, 2019
Interest rate													15%
Debt conversion converted instrument																					42,720
Debt instrument debt default interest rate													15%
Debt instrument face amount													$ 108,000			65,280	65,280		65,280		65,280
Accrued interest																$ 25,930	28,398		$ 25,930		7,232
Debt instrument periodic payment principal													3,000
Original issue discount													5,000
Convertible debt													$ 100,000
Debt instrument description													The conversion price for the October 3, 2019 Crown Bridge Note shall be equal to 60% ( representing a 40% discount) of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received
Debt instrument unamortized premium													$ 72,000								$ 28,480
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate													110%
Percentage of outstanding shares of common stock													4.99%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate													150%
Percentage of outstanding shares of common stock													9.99%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | October 21 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date											Oct. 21, 2022
Interest rate											8%
Debt instrument face amount											$ 63,750
Debt issue costs											$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | November 26 2021 [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date										Nov. 26, 2022
Interest rate										8%
Debt instrument face amount										$ 53,750
Debt issue costs										$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | January 4, 2022 [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date								Jan. 04, 2023
Interest rate								8%
Debt instrument face amount								$ 63,750
Debt issue costs								$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | March 7, 2022 [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date							Mar. 07, 2023
Interest rate							8%
Debt instrument face amount							$ 68,750
Debt issue costs							$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | April 12 2022 [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date					Apr. 12, 2023
Interest rate					8%
Debt instrument face amount					$ 68,750
Debt issue costs					$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | May 12, 2022 1800 Diagonal Note [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date				May 12, 2023
Interest rate				8%
Debt instrument face amount				$ 63,750
Debt issue costs				$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | July 11 2022 1800 Diagonal Note [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date																Jul. 11, 2022
Interest rate																8%			8%
Debt conversion converted instrument																	132,500
Debt instrument debt default interest rate																65%
Debt instrument face amount																$ 105,000	237,500		$ 105,000
Accrued interest																	$ 5,838
Debt instrument description																The conversion price for the above 1800 Diagonal notes shall be equal to 65% (representing a 35% discount) of the market price which means the average of the lowest three trading prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion.
Percentage of outstanding shares of common stock																	150%
Debt instrument unamortized premium																$ 262,500	$ 71,346		262,500
Debt issue costs																3,750
Debt instrument amount																$ 56,538			56,538
Debt default amount percentage																22%
Penalty amount																	1,000
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | July 11 2022 1800 Diagonal Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate																110%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | July 11 2022 1800 Diagonal Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate																129%
Percentage of outstanding shares of common stock																9.99%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date		Aug. 15, 2023
Debt conversion converted instrument																	115,700
Debt instrument debt default interest rate		6,500%
Debt instrument face amount		$ 110,000															230,000
Accrued interest																	7,438
Debt instrument description		The conversion price for the above ONE44 notes shall be equal to 65% (representing a 35% discount) of the market price which means the lowest closing bid prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion.
Percentage of outstanding shares of common stock		4.99%
Debt instrument unamortized premium		$ 215,385															62,300
Debt instrument amount		$ 59,231
Debt default amount percentage		24%
Debt conversion original debt		$ 10,000
Legal fees		$ 5,500
Debt principal increase percentage		20%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate		120%
Penalty amount		$ 250
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate		135%
Penalty amount		$ 500
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | December 7, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date									Dec. 07, 2022
Interest rate									10%
Debt instrument face amount									$ 170,000
Original issue discounts amount									$ 25,500
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | March 29, 2022 Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date						Mar. 29, 2023
Interest rate						10%
Debt conversion converted instrument																			54,300
Debt instrument face amount						$ 120,000										$ 235,700			235,700
Accrued interest																9,519			9,519
Debt instrument unamortized premium																29,238			29,238
Original issue discounts amount						$ 18,000
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument maturity date	Mar. 21, 2023		Apr. 12, 2023
Interest rate	8%		8%
Lowest trading price percentage	65%		65%
Debt instrument debt default interest rate	24%
Debt instrument face amount	$ 71,500		$ 93,000														164,500
Accrued interest																	$ 1,140
Original issue discount	$ 4,000		$ 5,000
Percentage of outstanding shares of common stock	4.99%		4.99%
Legal fees	$ 2,500		$ 3,000
Debt principal increase percentage	20%
Conversion price, description	The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of the Company’s common stock (the “Common Stock”) at a price for each share of Common Stock (“Conversion Price”) of $0.002 per share (the “Fixed Price”). However, in the event the Company’s Common Stock trades below $0.0014 per share for more than five (5) consecutive trading days, then the Fixed Price shall be equal to $0.0009 per share.		The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock (“Conversion Price”) of $0.0028 per share (the “Fixed Price”). However, in the event the Company’s common stock trades below $0.002 per share for more than five (5) consecutive trading days, then the Fixed Price shall be equal to $0.0013 per share.
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate	110%
Penalty amount	$ 250
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument debt default interest rate	125%
Penalty amount	$ 500
6th Street Financing Agreement [Member] | 1800 Diagonal Lending [Member] | May 12, 2022 1800 Diagonal Note [Member]
Short-Term Debt [Line Items]
Debt conversion converted instrument																			117,500
Debt instrument face amount																265,000			265,000
Accrued interest																6,081			6,081
Debt instrument unamortized premium																$ 63,269			$ 63,269

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details)	3 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance | shares	105,420
Weighted Average Price Per Share, Outstanding, Beginning balance | $ / shares	$ 200.27
Number of Shares, Issued | shares	3,305,000
Weighted Average Price Per Share, Issued | $ / shares	$ 0.01
Number of Shares, Exercised | shares	(3,292)
Weighted Average Price Per Share, Exercised | $ / shares	$ 78.49
Number of Shares, Forfeited | shares	(1,000)
Weighted Average Price Per Share Forfeited | $ / shares	$ 2,000
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired | $ / shares
Number of Shares, Outstanding, Ending balance | shares	3,406,128	[1]
Weighted Average Price Per Share, Outstanding, Ending balance | $ / shares	$ 5.55
Number of Shares, Exercisable, Ending balance | shares	3,379,879
Weighted Average Price Per Share, Exercisable, Ending balance | $ / shares	$ 2.83
Weighted average remaining contractual term	2 years 9 months 29 days
Aggregate intrinsic value | $
[1]The total warrants of 3,406,128

SCHEDULE OF WARRANT ACTIVITY _2

SCHEDULE OF WARRANT ACTIVITY (Details) (Parenthetical) - shares	Sep. 30, 2022		Jun. 30, 2022
Equity [Abstract]
Total warrants	3,406,128	[1]	105,420
[1]The total warrants of 3,406,128

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE (Details) - shares	Sep. 30, 2022		Jun. 30, 2022
Class of Stock [Line Items]
Number of warrants	3,406,128	[1]	105,420
Exercisable	3,379,879
Series A Warrants [Member]
Class of Stock [Line Items]
Number of warrants	10,154
Exercisable	10,154
Series B Warrants [Member]
Class of Stock [Line Items]
Number of warrants	26,250
Exercisable	26,250
Series C Warrants [Member]
Class of Stock [Line Items]
Number of warrants	63,749
Exercisable	37,500
Warrants With No Class Designation [Member]
Class of Stock [Line Items]
Number of warrants	3,305,975
Exercisable	3,305,975
[1]The total warrants of 3,406,128

SCHEDULE OF SHARE BASED COMPENS

SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY (Details)	3 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance | shares	59
Weighted Average Price Per Share, Outstanding, Beginning balance | $ / shares	$ 4,533
Number of Shares, Granted | shares
Weighted Average Price Per Share, Granted | $ / shares
Number of Shares, Exercised | shares
Weighted Average Price Per Share, Exercised | $ / shares
Number of Shares, Forfeited | shares
Weighted Average Price Per Share, Forfeited | $ / shares
Number of Shares, Expired | shares
Weighted Average Price Per Share, Expired | $ / shares
Number of Shares, Outstanding, Ending balance | shares	59
Weighted Average Price Per Share, Outstanding, Ending balance | $ / shares	$ 4,533
Number of Shares, Exercisable, Ending balance | shares	59
Weighted Average Price Per Share, Exercisable, Ending balance | $ / shares	$ 4,533
Weighted average remaining contractual term	6 years 7 months 13 days
Weighted average fair value of options granted during the period	0 years
Aggregate intrinsic value | $

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative)										1 Months Ended				2 Months Ended		3 Months Ended		14 Months Ended
	Nov. 03, 2022 USD ($)	Sep. 21, 2022 $ / shares shares	Sep. 09, 2022 USD ($) shares	Aug. 16, 2022 USD ($) $ / shares shares	Jul. 29, 2022 shares	Jul. 13, 2022 USD ($) $ / shares shares	Jul. 02, 2022 shares	May 18, 2022 $ / shares shares	Nov. 30, 2021 USD ($)	Oct. 31, 2022 USD ($) shares	Sep. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	May 31, 2019 USD ($) $ / shares shares	Nov. 30, 2022 USD ($) $ / shares shares	Sep. 14, 2022 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Sep. 14, 2022 shares	Sep. 20, 2022 shares	Jul. 12, 2022 shares	May 17, 2022 shares	Sep. 30, 2020 shares
Class of Stock [Line Items]
Common stock per share | $ / shares		$ 0.001						$ 0.001			$ 0.001	$ 0.001				$ 0.001
Common Stock, Shares Authorized | shares		10,000,000,000						3,000,000,000			10,000,000,000	10,000,000,000				10,000,000,000			3,000,000,000		1,000,000,000
Number of preferred stock authorized shares | shares		1,500,005						1,500,005
Preferred stock, shares authorized | shares		10,001,500,005						3,001,500,005			1,500,005	1,500,005				1,500,005
Preferred stock, par value | $ / shares											$ 0.01	$ 0.01				$ 0.01
Preferred stock shares outstanding | shares		1,500,005
Stock issued during period, value																$ 48,469
Aggregate value											$ 677,178	$ 220,351				677,178
Issuance of stock | shares		10,001,500,005						3,001,500,005
Proceeds from issuance of common stock						$ 24,711										24,711
Subscription receivable value																$ 23,758
Common Stock, Shares, Issued | shares											677,177,717	220,350,921				677,177,717
Principal amount											$ 79,000					$ 79,000
Interest payable current and non current											48,922	$ 57,822				48,922
Reclassified premium amount for additional paid in capital																133,646	109,643
Accrued interest											9,543					9,543
Debt instrument fair value											195,952					195,952
Loss on extinguishment debt conversion											107,409					107,409
Derivative fair value											$ 106,799					106,799
Gain on extinguishment debt conversion																610
Stock issued during period shares | shares							12,270,958					12,270,958
Proceeds from the exercise of warrants			$ 100,000													$ 100,000	275,000
Number of shares, exercised | shares
Deemed dividend																$ 389,235
Restricted stock units, value | $ / shares
Share based compensation																$ 0	20,718
Gains losses on extinguishment of debt																(610)
Unvested stock option expense																$ 0
Stock options granted | shares																0
2019 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance | shares											234					234
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares													117
Restricted stock units, value | $ / shares													$ 4,250
Fair value granted, shares													$ 497,240
Unrecognized restricted stock units expense																$ 248,620
Restricted stock units not yet vested, shares											$ 248,620	$ 248,620				$ 248,620
Unvested Restricted Stock Units [Member]
Class of Stock [Line Items]
Unvested restricted stock units | shares											59					59
Chief Executive Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares													78
Chief Scientific Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares													39
Series A And C Warrant [Member]
Class of Stock [Line Items]
Issuance of stock | shares																158,399,208
Series A Warrants [Member]
Class of Stock [Line Items]
Warrants exercise price | $ / shares											$ 792					$ 792
Warrants exercise price | $ / shares											200					200
Alternate cashless warrant exercise price | $ / shares											0.001					$ 0.001
Percentage of exercise price and market price																70%
Subsequent Event [Member]
Class of Stock [Line Items]
Issuance of stock | shares														97,854,629
Debt Instrument, Convertible, Conversion Price | $ / shares														$ 0.001
Principal amount														$ 57,400
Deemed dividend										$ 19,322
Convertible Debt [Member]
Class of Stock [Line Items]
Issuance of stock | shares																		264,492,661
Proceeds from issuance of common stock															$ 456,939
Common Stock, Shares, Issued | shares												7,326,007								7,326,007
Debt Instrument, Convertible, Conversion Price | $ / shares											$ 0.001					$ 0.001
Principal amount											$ 327,200					$ 327,200
Interest payable current and non current											$ 22,330					$ 22,330
Convertible Debt [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Volatility											0					0
Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Volatility											3.92					3.92
Convertible Debt [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Volatility											250.04					250.04
Common Stock [Member]
Class of Stock [Line Items]
Common stock per share | $ / shares		$ 0.001						$ 0.001
Stock issued during period, value																$ 14,337
Issuance of stock | shares						14,336,712										14,336,712
Share issued per share | $ / shares						$ 0.002
Reclassified premium amount for additional paid in capital
Number of shares, exercised | shares			1,250		1,250
Common Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued | shares										1,250
Warrant [Member]
Class of Stock [Line Items]
Common stock per share | $ / shares				$ 0.01
Warrants to purchase common stock | shares				1,000,000
Warrants expiration date				Aug. 16, 2025
Fair market value of warrants				$ 2,408
Stock valuation price per share | $ / shares				$ 0.0026
Warrant exercise price | $ / shares				$ 0.01
Share based compensation																$ 2,408
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Volatility				0
Warrant [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term				3 years
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Volatility				0.0319
Warrant [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Volatility				2.36
Maximum [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term																6 months 10 days
Maximum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized | shares		10,000,000,000						3,000,000,000
Common Stock Purchase Agreement [Member] | Dutchess [Member]
Class of Stock [Line Items]
Agreement term	36 months								36 months
Lowest trading price									92%
Percentage of average daily trading volume									300%
Aggregate value									$ 250,000
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Percentage of average daily trading volume	200%
Aggregate value	$ 250,000
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock issued during period, value									$ 5,000,000
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Maximum [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Stock issued during period, value	$ 5,000,000
Underlying Financing Agreements [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance | shares											1,565,029,216					1,565,029,216
Affiliated Entity [Member] | Warrant [Member]
Class of Stock [Line Items]
Common stock per share | $ / shares				$ 0.01
Gain on extinguishment debt conversion											$ (17,499)
Warrants to purchase common stock | shares				2,305,000
Fair market value of warrants				$ 5,551
Stock valuation price per share | $ / shares				$ 0.0026
Warrant exercise price | $ / shares				$ 0.01
Warrants outstanding payable				$ 23,050
Gains losses on extinguishment of debt											$ 17,499
Affiliated Entity [Member] | Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Class of Stock [Line Items]
Volatility				0
Affiliated Entity [Member] | Warrant [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Maturity term				3 years
Affiliated Entity [Member] | Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Volatility				0.0319
Affiliated Entity [Member] | Warrant [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Volatility				2.36
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares											500,000	500,000				500,000						500,000
Preferred stock, par value | $ / shares											$ 0.01	$ 0.01				$ 0.01
Preferred stock shares issued | shares											500,000	500,000				500,000
Preferred stock shares outstanding | shares											500,000	500,000				500,000
Stock issued during period, shares | shares											0					0
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares											5	5				5
Preferred stock, par value | $ / shares											$ 0.01	$ 0.01				$ 0.01
Preferred stock shares issued | shares											1	1				1
Preferred stock shares outstanding | shares											1	1				1
Stock issued during period, shares | shares											0					0
Series B Preferred Stock [Member] | Nathanielsz [Member]
Class of Stock [Line Items]
Beneficial ownership shares | shares											1					1
Series B Warrants [Member]
Class of Stock [Line Items]
Number of shares, exercised | shares			2,500
Series B Warrants [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of shares, exercised | shares										1,250
Series A Warrant [Member]
Class of Stock [Line Items]
Warrants exercise price | $ / shares											$ 200					$ 200

SCHEDULE OF RIGHT USE OF ASSET

SCHEDULE OF RIGHT USE OF ASSET (Details) - USD ($)	Sep. 30, 2022	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Office lease	$ 66,201	$ 66,201
Less: accumulated amortization	(13,176)	(3,678)
Right-of-use asset, net	$ 53,025	$ 62,523

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - USD ($)	Sep. 30, 2022	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Office lease	$ 66,201	$ 66,201
Reduction of lease liability	(12,322)	(3,277)
Less: office lease, current portion	(14,516)	(20,605)
Long term portion of lease liability	$ 39,363	$ 42,319

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)	Sep. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal Year 2023	$ 17,366
Fiscal Year 2024	23,155
Fiscal Year 2025	19,296
Imputed interest	(5,938)
Total operating lease liability	$ 53,879

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)

1 Months Ended

3 Months Ended

12 Months Ended

Jul. 27, 2022 USD ($)

Jul. 27, 2022 EUR (€)

Jul. 02, 2022 USD ($)

May 04, 2022 USD ($)

May 04, 2022 AUD ($)

Oct. 02, 2020 USD ($)

Oct. 02, 2020 EUR (€)

Sep. 13, 2018 USD ($)

Sep. 13, 2018 EUR (€)

Jul. 31, 2023 USD ($)

Jul. 31, 2023 EUR (€)

Mar. 31, 2023 USD ($)

Mar. 31, 2023 EUR (€)

Dec. 31, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Sep. 30, 2022 USD ($)

Sep. 30, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€)

Mar. 31, 2021 USD ($)

Mar. 31, 2021 EUR (€)

Nov. 30, 2020 EUR (€)

Jun. 30, 2012

Sep. 30, 2022 USD ($)

Sep. 30, 2021 USD ($)

Jun. 30, 2021 USD ($)

Jun. 30, 2021 EUR (€)

Jun. 30, 2019 USD ($)

Jun. 30, 2019 EUR (€)

Jun. 30, 2022 USD ($)

Total litigation penalty amount

$ 30,000

Payment for services

$ 24,043

€ 28,493

$ 36,117

€ 31,754

Royalties percentage

2%

2%

unreimbursed lab fees

$ 13,360

13,360

$ 14,364

Payments for Rent

6,373

$ 7,736

Operating Lease, Right-of-Use Asset

$ 53,025

$ 53,025

$ 62,523

Weighted average remaining lease term

2 years 6 months 7 days

2 years 6 months 7 days

Accounting Standards Update 2016-02 [Member]

Operating Lease, Right-of-Use Asset

$ 66,201

Operating Lease, Liability

$ 66,201

University of Jaen [Member]

Payment for services

$ 30,268

€ 25,837

Royalty Agreement Terms [Member]

Operating leases income statement revenue percentage

2%

License Agreement Terms [Member]

Operating leases income statement revenue percentage

5%

1-Year Collaboration Agreement [Member]

Payment for services

$ 59,508

€ 52,000

2-Year Collaboration Agreement [Member]

Payment for services

$ 35,145

€ 30,000

$ 45,775

€ 40,000

Research Agreement [Member]

Payment for services

$ 53,806

€ 53,200

Research Agreement [Member] | University of Jaen [Member] | Revenue Benchmark [Member] | Revenue from Rights Concentration Risk [Member] | No Customer [Member]

Royalties percentage

2%

2%

Consulting Agreement [Member]

Monthly Fee

$ 50,000

Stock fee percentage

9.90%

Accrued expense

$ 54,765

$ 54,765

New Five-Year Operating Lease Agreement [Member]

Lessee, Operating Lease, Term of Contract

3 years

Payments for Rent

$ 2,176

$ 3,000

From 2012 through the 2014 [Member]

Total litigation penalty amount

$ 10,000

Installment 1 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services | €

€ 5,000

Installment 1 [Member] | Research Agreement [Member]

Payment for services

$ 18,407

€ 18,200

Installment 2 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 5,858

€ 5,000

Installment 2 [Member] | Research Agreement [Member]

Payment for services

8,091

€ 8,000

Installment 3 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 3 [Member] | Research Agreement [Member]

Payment for services

$ 7,080

€ 7,000

Installment 4 [Member] | 2-Year Collaboration Agreement [Member]

Payment for services

$ 11,715

€ 10,000

Installment 4 [Member] | Research Agreement [Member] | Forecast [Member]

Payment for services

$ 10,114

€ 10,000

Installment 5 [Member] | Research Agreement [Member] | Forecast [Member]

Payment for services

$ 10,114

€ 10,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)

1 Months Ended

3 Months Ended

12 Months Ended

Oct. 26, 2022 USD ($)

Oct. 26, 2022 AUD ($)

Aug. 02, 2022 USD ($)

Aug. 02, 2022 AUD ($)

Aug. 02, 2022 USD ($)

Aug. 02, 2022 AUD ($)

May 04, 2022 USD ($)

May 04, 2022 AUD ($)

Aug. 12, 2021 USD ($) shares

Jul. 13, 2020 AUD ($)

May 14, 2019 USD ($) $ / shares shares

May 14, 2019 AUD ($) shares

Mar. 16, 2018 USD ($)

Mar. 16, 2018 AUD ($)

Feb. 01, 2018 USD ($)

Feb. 01, 2018 AUD ($)

Feb. 25, 2016 USD ($)

Feb. 25, 2016 AUD ($)

Feb. 25, 2015 AUD ($)

May 31, 2019 shares

Sep. 30, 2022 USD ($) $ / shares shares

Sep. 30, 2022 AUD ($) shares

Sep. 30, 2021 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2022 AUD ($)

Jun. 30, 2021 USD ($) shares

Jun. 30, 2021 AUD ($) shares

Jun. 30, 2020 USD ($)

Jun. 30, 2020 AUD ($)

Jun. 30, 2019 USD ($)

Jun. 30, 2019 AUD ($)

Sep. 30, 2022 AUD ($)

Jun. 30, 2022 AUD ($)

Related Party Transaction [Line Items]

Due to related parties | $

$ 28,599

$ 30,746

Payments for rent | $

6,373

$ 7,736

Bonus payable

$ 26,620

$ 41,387

99,691

$ 144,166

Exercise price | $ / shares

Granted exercise price | $ / shares

Accrued salaries

$ 43,416

37,341

$ 67,500

$ 54,000

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Payments form related party

$ 221,890

$ 136,606

$ 202,620

$ 64,377

$ 90,000

Bonus payable amount

137,120

200,000

Remaining bonus amount

$ 90,007

139,937

125,386

181,324

$ 178,256

$ 260,000

Bonus payable

$ 166,418

$ 422,610

$ 280,726

$ 407,380

Restricted stock shares of common stock

78

Nathanielsz Employment Agreement [Member]

Related Party Transaction [Line Items]

Expired date

Feb. 25, 2019

Annual salary

$ 25,000

$ 300,000

205,680

Percentage of pension of monthly salary

9.50%

9.50%

Percentage of bonus of annual base salary

200%

200%

Nathanielsz Employment Agreement [Member] | Subsequent Event [Member]

Related Party Transaction [Line Items]

Annual salary

$ 414,900

$ 600,000

Nathanielsz Employment Agreement [Member] | Maximum [Member]

Related Party Transaction [Line Items]

Annual salary

$ 414,900

$ 600,000

$ 274,240

$ 400,000

Percentage of bonus of annual base salary

200%

100%

100%

Nathanielsz Employment Agreement [Member] | Minimum [Member]

Related Party Transaction [Line Items]

Annual salary

$ 276,600

$ 400,000

$ 205,680

$ 300,000

Mrs. Nathanielsz [Member] | Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Bonus payable | $

$ 316,957

Employment Agreement [Member]

Related Party Transaction [Line Items]

Restricted stock unit shares upon vest

39

39

Employment Agreement [Member] | Initial Nathanielsz RSUs [Member]

Related Party Transaction [Line Items]

Restricted stock shares of common stock

39

39

Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]

Related Party Transaction [Line Items]

Restricted stock unit issuable

39

39

Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]

Related Party Transaction [Line Items]

Grand date fair value, per share | $ / shares

$ 7.80

Gross proceeds from equity financing | $

$ 4,000,000

Services Agreement [Member]

Related Party Transaction [Line Items]

Restricted stock unit issuable

20

20

Services Agreement [Member] | Initial Kenyon RSUs [Member]

Related Party Transaction [Line Items]

Restricted stock shares of common stock

20

20

Services Agreement [Member] | Additional Kenyon RSUs [Member]

Related Party Transaction [Line Items]

Restricted stock shares of common stock

20

20

Gross proceeds from equity financing | $

$ 4,000,000

Restricted stock unit shares upon vest

5

5

North Horizon Pty Ltd [Member]

Related Party Transaction [Line Items]

Lessor, Operating lease, term of contract

3 years

3 years

Operating leases rent expense, minimum rentals

$ 2,176

$ 3,000

Former Director [Member]

Related Party Transaction [Line Items]

Loans from related party | $

$ 28,599

30,746

Due to related parties | $

47,597

51,171

Nathanielsz [Member] | North Horizon Pty Ltd [Member]

Related Party Transaction [Line Items]

Operating leases, future minimum payments due

$ 84,342

84,452

$ 131,129

$ 122,129

Mrs. Nathanielsz [Member]

Related Party Transaction [Line Items]

Annual salary

$ 80,904

$ 120,000

Payments form related party

$ 5,577

$ 7,689

James Nathanielsz [Member]

Related Party Transaction [Line Items]

Payments form related party

$ 3,205

$ 4,481

Mr. Nathanielsz [Member] | Board of Directors [Member]

Related Party Transaction [Line Items]

Officers compensation

$ 96,810

$ 140,000

$ 177,840

$ 240,000

$ 315,376

$ 460,000

Debt conversion, converted instrument, shares issued

5,928,000

Mr. Nathanielsz [Member] | Board of Directors [Member] | AUD Currency [Member]

Related Party Transaction [Line Items]

Bonus granted percentage

60%

Mr. Nathanielsz [Member] | Employment Agreement [Member]

Related Party Transaction [Line Items]

Annual salary | $

$ 400,000

Agreement term

3 years

3 years

Agreement renewal term

1 year

1 year

Option purchase shares

39

39

Exercise price | $ / shares

$ 4,675

Market price

110%

110%

Granted exercise price | $ / shares

$ 4,250

Options vested, description

The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz’s continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz’s continued employment with the Company through the applicable vesting date: (i) 7.80 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the “CTA”) for PRP, the Company’s lead product candidate (“PRP”), for a First-In-Human study for PRP (the “Study”) in an applicable jurisdiction to be selected by the Company, (ii) 7.80 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7.80 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7.80 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7.80 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study.

The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz’s continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz’s continued employment with the Company through the applicable vesting date: (i) 7.80 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the “CTA”) for PRP, the Company’s lead product candidate (“PRP”), for a First-In-Human study for PRP (the “Study”) in an applicable jurisdiction to be selected by the Company, (ii) 7.80 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7.80 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7.80 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7.80 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study.

Option term

10 years

10 years

Dr. Kenyon [Member] | Services Agreement [Member]

Related Party Transaction [Line Items]

Agreement term

3 years

3 years

Agreement renewal term

1 year

1 year

Option purchase shares

20

20

Exercise price | $ / shares

$ 4,250

Market price

100%

100%

Options vested, description

The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon’s continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon’s continued employment with the Company through the applicable vesting date: (i) 5 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 5 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii)

The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon’s continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon’s continued employment with the Company through the applicable vesting date: (i) 5 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 5 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii)

Option term

10 years

10 years

Dr. Kenyon [Member] | Cancellation Agreement [Member]

Related Party Transaction [Line Items]

Debt conversion, converted instrument, shares issued

3,420,000

Cancellation of accrued salary | $

$ 102,600

Dr Kenyon [Member] | Services Agreement [Member]

Related Party Transaction [Line Items]

Annual salary | $

$ 54,000

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022
Concentration Risk [Line Items]
Discounts and debt issuance cost	$ 33,750	$ 7,500
Proceeds from convertible debt	$ 345,750	160,000
Lender [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt		$ 160,000
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk percentage		100%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	29%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	27%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	44%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100%		100%
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 101,250
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	94,500
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 150,000

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details) - Convertible Debt [Member]	3 Months Ended
	Sep. 30, 2022
Measurement Input, Price Volatility [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	250.04
Measurement Input, Price Volatility [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	228.29
Measurement Input, Price Volatility [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	250.04
Measurement Input, Expected Term [Member] | Minimum [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	5 months 19 days
Measurement Input, Expected Term [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	6 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	6 months 10 days
Measurement Input, Expected Term [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, term	8 months 1 day
Measurement Input, Risk Free Interest Rate [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	3.92
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	3.13
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	3.86
Measurement Input, Expected Dividend Rate [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	0
Measurement Input, Expected Dividend Rate [Member] | New Derivative Instruments [Member]
Derivative [Line Items]
Debt instrument, measurement input, percentages	0

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Sep. 30, 2022	Jun. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Embedded conversion option liabilities	$ 72,958	$ 151,262
Total	72,958	151,262
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Embedded conversion option liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Embedded conversion option liabilities	72,958	151,262
Total	$ 72,958	$ 151,262

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Balance at Beginning	$ 151,262
Initial fair value of embedded conversion option derivative liability recorded as debt discount	93,668
Reduction of derivative liability upon debt conversion	(106,799)
Change in fair value included in statements of operations	(65,173)	$ 3,904
Balance at Ending	$ 72,958

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Sep. 30, 2022	Jun. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Share price	$ 0.0012
Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Convertible debt	$ 164,500	$ 79,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)								1 Months Ended	2 Months Ended	3 Months Ended		13 Months Ended
	Nov. 03, 2022 USD ($) $ / shares shares	Oct. 26, 2022 USD ($)	Oct. 06, 2022 USD ($)	Sep. 21, 2022 $ / shares shares	Jul. 13, 2022 shares	May 18, 2022 $ / shares shares	Nov. 30, 2021 USD ($)	Oct. 31, 2022 USD ($) shares	Nov. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Oct. 31, 2022 USD ($) $ / shares shares	Oct. 26, 2022 AUD ($)	Sep. 30, 2022 AUD ($) shares	Sep. 20, 2022 shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 AUD ($) shares	May 17, 2022 shares
Subsequent Event [Line Items]
Issuance of stock | shares				10,001,500,005		3,001,500,005
Convertible debt principal amount										$ 79,000
Proceeds from convertible debt										345,750	$ 160,000
Debt instrument unamortized premium										295,250						$ 313,127
Deemed dividend										$ 389,235
Common stock shares issued | shares										677,177,717				677,177,717		220,350,921	220,350,921
Weighted Average Price Per Share, Granted | $ / shares
Base salary per annum										$ 43,416				$ 67,500		$ 37,341	$ 54,000
Common stock, par value per share | $ / shares				$ 0.001		$ 0.001				$ 0.001						$ 0.001
Common stock, shares authorized | shares				10,000,000,000		3,000,000,000				10,000,000,000				10,000,000,000	3,000,000,000	10,000,000,000	10,000,000,000	1,000,000,000
Preferred stock, shares remains | shares				1,500,005
Number of shares authorized to issue | shares				10,001,500,005		3,001,500,005				1,500,005				1,500,005		1,500,005	1,500,005
Stock issued during period, value										$ 48,469
Aggregate value										677,178						$ 220,351
Debt instrument unamortized discount										127,811						$ 31,669
Debt discount to be amortized										$ 31,275	6,074
Common Stock [Member]
Subsequent Event [Line Items]
Issuance of stock | shares					14,336,712					14,336,712
Common stock, par value per share | $ / shares				$ 0.001		$ 0.001
Stock issued during period, value										$ 14,337
Common Stock [Member] | Maximum [Member]
Subsequent Event [Line Items]
Common stock, shares authorized | shares				10,000,000,000		3,000,000,000
Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Debt instrument unamortized discount										115,769	90,192
Debt discount to be amortized										$ 127,418	$ 7,500
Common Stock Purchase Agreement [Member] | Dutchess [Member]
Subsequent Event [Line Items]
Agreement term	36 months						36 months
Percentage of average daily trading volume							300%
Aggregate value							$ 250,000
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Maximum [Member]
Subsequent Event [Line Items]
Stock issued during period, value							$ 5,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Issuance of stock | shares									97,854,629
Conversion price | $ / shares									$ 0.001
Convertible debt principal amount									$ 57,400
Premiums to additional paid in capital									$ 30,908
Deemed dividend								$ 19,322
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Common stock shares issued | shares								1,250				1,250
Subsequent Event [Member] | Common Stock [Member] | Consultant [Member]
Subsequent Event [Line Items]
Stock issued during period shares for services | shares												6,111,112
Weighted Average Price Per Share, Granted | $ / shares												$ 0.0009
Share based consulting expense												$ 5,500
Subsequent Event [Member] | Series A Warrant [Member]
Subsequent Event [Line Items]
Issuance of stock | shares								33,599,832
Subsequent Event [Member] | Series B Warrant [Member]
Subsequent Event [Line Items]
Proceeds from issuance of warrants												$ 50,000
Exercise of warrants | shares								1,250				1,250
Subsequent Event [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Monthly payment amount	$ 19,643
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Red Road Holdings Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Convertible debt principal amount			$ 53,750
Proceeds from convertible debt			$ 50,000
Debt instrument, interest rate, stated percentage			8%
Debt instrument debt default interest rate			22%
Legal fees and due diligence expenses			$ 3,750
Debt instrument description			The “Variable Conversion Price” shall mean 65% multiplied by the Market Price (as defined herein) (representing a discount rate of 35%). “Market Price” means the average of the lowest three (3) Trading Prices (as defined below) for the common stock during the ten (10) trading days prior to the conversion date. Notwithstanding the foregoing, Red Road shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Red Road and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock. This note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a total of $28,942 put premium.
Percentage of outstanding shares of common stock			4.99%
Debt instrument unamortized premium			$ 28,942
Note prepayment premium description			The Note may be prepaid until 180 days from the issuance date. If the Note is prepaid within 60 days of the issuance date, then the prepayment premium shall be 110% of the face amount plus any accrued interest, if prepaid after 60 days from the issuance date, but less than 91 days from the issuance date, then the prepayment premium shall be 115% of the face amount plus any accrued interest, if prepaid after 90 days from the issuance date, but less than 121 days from the issuance date, then the prepayment premium shall be 120% of the face amount plus any accrued interest, if prepaid after 120 days from the issuance date, but less than 151 days from the issuance date, then the prepayment premium shall be 125% of the face amount plus any accrued interest, and if prepaid after 150 days from the issuance date, but less than 181 days from the issuance date, then the prepayment premium shall be 129% of the face amount plus any accrued interest. So long as the Note is outstanding, the Company covenants not to, without prior written consent from Red Road, sell, lease or otherwise dispose of all or substantially all of its assets outside the ordinary course of business which would render the Company a “shell company” as such term is defined in Rule 144.
Penalty amount			$ 1,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Coventry Enterprises LLC Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Convertible debt principal amount	125,000
Proceeds from convertible debt	$ 100,000
Debt instrument, interest rate, stated percentage	1,000%
Debt instrument unamortized discount	$ 25,000
Debt instrument guaranteed interest	$ 12,500
Number of shares issued | shares	75,000,000
Stock valuation price per share | $ / shares	$ 0.0008
Debt discount to be amortized	$ 60,000
Subsequent Event [Member] | Amended And Restated Employment Agreement [Member]
Subsequent Event [Line Items]
Base salary per annum		$ 414,900											$ 600,000
Percentage of bonus of annual base salary		200%
Subsequent Event [Member] | Amended And Restated Employment Agreement [Member] | Maximum [Member]
Subsequent Event [Line Items]
Percentage of bonus of annual base salary		100%
Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | Dutchess [Member]
Subsequent Event [Line Items]
Percentage of average daily trading volume	200%
Aggregate value	$ 250,000
Beneficial ownership limitation, percentage	9.99%
Subsequent Event [Member] | Common Stock Purchase Agreement [Member] | Dutchess [Member] | Maximum [Member]
Subsequent Event [Line Items]
Stock issued during period, value	$ 5,000,000